A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s Disease
- Conditions
- Crohn's diseaseMedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- EUCTR2018-002001-65-GB
- Lead Sponsor
- niversity of Birmingham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 36
A patient will be eligible for inclusion in this study only if all of the following criteria apply:
1.Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications. (see Section 7.11 for additional information)
2.Patients that have been diagnosed with moderate to severe Crohn’s disease for at least 3 months prior to Screening Visit 1 defined by CDAI score between 220-450
3.Patients are required to have endoscopic evidence of active Crohn’s disease at Baseline (screening visit 1) defined by endoscopic appearance: SES-CD excluding the narrowed component of = 6 (or =4 for patients with isolated ileal disease).
4.AST and ALT = 2xULN; alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
5.Male or female participants aged =16 years (up to 80 years)
Male participants:
6.A male participant must agree to use contraception as detailed in Appendix 5 of this protocol for at least 180 days post-dose of study medication and refrain from donating sperm during this period.
Female participants:
7.A female participant is eligible to participate if she is not pregnant or breastfeeding and not a woman of childbearing potential (WOCBP) defined as at least one of the following conditions:
i.Premenopausal female with documented hysterectomy
iiPremenopausal female with documented bilateral salpingectomy or oophorectomy
iii.Postmenopausal female defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
iv.Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the trial. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before trial enrolment.
v.A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 for at least 180 days post-dose of trial medication. If a hormonal method of birth control is selected from the list in Appendix 1 then participants must have been using these methods at least 28 days prior to GSK1070806 administration, or be abstinent, or utilise a condom as a method of contraception until the selected hormonal method has been in place for the 28 day period.
Are the trial subjects under 18? yes
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 34
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 1
A participant will not be eligible for inclusion in this trial if any of the following criteria apply:
1.Diagnosis of ulcerative or indeterminate colitis
Crohn’s Disease complications:
2.Evidence of an infected abscess by MRI or other examinations
3.Bowel surgery other than appendectomy within 12 weeks prior to screen and/or has planned surgery or deemed likely to need surgery for CD during the trial period
4.Participants with ileostomies, colostomies or rectal pouches
5.Participants with a bowel stricture that is fixed
6.Participants with evidence of short bowel syndrome
7.Participants requiring enteral or parenteral feeding
8.Deep penetrating ulcers at endoscopy thought to be at risk for perforation
Viral and bacterial infections:
9.Presence of Hepatitis B surface antigen (HBsAg), (confirmed by Hepatitis B surface antigen test – within 12 months of randomisation) core antigen (HBcAg) or surface antibody (HBsAb), positive Hepatitis C (qualitative enzyme immunoassay) test result
10.Known varicella, herpes zoster, or other severe viral infection within 6 weeks of randomisation
11.The participant has a history of tuberculosis (TB) disease or latent TB infection, in the absence of documented adequate therapy for same.
12.Positive screening test for TB (including T-SPOT.TB TB test), unless respiratory review confirms false positive test results
13.History of uncontrolled bacterial or fungal infection requiring intravenous antibiotics
14.Positive immunoassay for Clostridium difficile toxin and other enteric pathogens
Other exclusion criteria:
15.Cardiology assessment/co-morbidity defined as:
i.QTc >450 msec (480msec for those with Bundle Branch Block) and/or
ii.either QTcb or QTcf, machine or manual overread, males or females. The QT correction formula used to determine exclusion and discontinuation should be the same throughout the trial and/or
iii.based on single QTc value (average of triplicate readings) of ECG obtained over a brief recording period
16.The participant has congenital or acquired immunodeficiency, or a history of chronic or recurrent opportunistic infections
17.The participant has current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or cancer in situ that has been resected)
18.Use of any investigational drug within 30 days prior to screening, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
19.Participant has received live, attenuated or recombinant vaccine(s) within 2 months of randomisation or will require vaccination within 3 months of trial drug infusion
20.Any patients that are receiving medication(s) detailed in Section 7.11.2 of the trial protocol, will not be eligible for randomisation into the trial
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method